peptidefix

Peptides / Sermorelin / United Kingdom

Sermorelin in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine. The MHRA products register returns no result for sermorelin (checked 2026-09-22).

As understood at 2026-09-22. Verify with the MHRA.

What Sermorelin is

Sermorelin is the first 29 amino acids of growth hormone-releasing hormone, the shortest fragment that still triggers the pituitary to release growth hormone. It was developed as a medicine for growth hormone deficiency in children and marketed under the name Geref; there is no current FDA label for it. In Australia it is a prescription-only substance.

Full Sermorelin page: targets and research →

Listed suppliers in the United Kingdom

3 of the 10 suppliers we list in the United Kingdom list Sermorelin. Listed, not endorsed: each row is the supplier’s own stated terms.

Bluewell Peptides United Kingdom All Bluewell products are supplied strictly for laboratory research use only. They are not intended for human consumption, medical use, therapeutic use, diagnostic use, or veterinary use. Research Peptide United Kingdom Supplied strictly for research and laboratory use only and not for human or veterinary consumption. UK Peptides United Kingdom All products are sold exclusively for in-vitro research. They are not for human or veterinary use.

Clinical Research

Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone
Neyzi O, Yordam N, Ocal G, et al. (1993). Acta Paediatrica. human 43 prepubertal children aged 4 to 19 with growth hormone deficiency of hypothalamic origin, randomised to three treatment groups for 6 months
Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration
Wilton P, Chardet Y, Danielson K, et al. (1993). Acta Paediatrica. human 30 healthy men aged 19 to 43, intravenous and intranasal administration
Intranasal administration of growth hormone-releasing hormone(1-29)-NH2 in children with growth hormone deficiency: effects on growth hormone secretion and growth
Hummelink R, Sippell WG, Benoit KG, et al. (1993). Acta Paediatrica. human 8 short prepubertal children with growth hormone deficiency, 6-month intranasal pilot study
Effects of long-term growth hormone releasing hormone 1-29 in significantly short children
Grunt JA, Schwartz ID, Buchanan C, Howard CP (1995). Acta Paediatrica. human 7 children with idiopathic short stature and normal growth hormone levels, treated up to 24 months